LncRNA BCLET Variant Confers Bladder Cancer Susceptibility Through Alternative Splicing of MSANTD2 Exon 1

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 May 22

PMID 37211917

Authors

Hanting Liu

Xi Wang

Zheng Guo

Guanting Sun

Qiang Lv

Chao Qin

Lin Yuan

Yunyan Wang

Mulong Du

Meilin Wang

Zhengdong Zhang

Haiyan Chu

Affiliations

Soon will be listed here.

Abstract

Background: Alternative splicing (AS)-related single nucleotide polymorphisms (SNPs) are associated with risk of cancers, but the potential mechanism has not been fully elucidated.

Methods: Two-stage case-control studies comprising 1630 cases and 2504 controls were conducted to investigate the association between the AS-SNPs and bladder cancer susceptibility. A series of assays were used to evaluate the functional effect of AS-SNPs on bladder cancer risk.

Results: We observed that SNP rs558814 A>G located in lncRNA BCLET (Bladder Cancer Low-Expressed Transcript, ENSG00000245498) can decrease the risk of bladder cancer (odds ratio [OR] = 0.84, 95% confidence interval [CI] = 0.76-0.92, p = 3.26 × 10 ). Additionally, the G allele of rs558814 had transcriptional regulatory effects and facilitated the expression of BCLET transcripts, including BCLET-long and BCLET-short. We also found decreased BCLET expression in bladder cancer tissues and cells, and BCLET transcript upregulation substantially inhibited tumor growth of both bladder cancer cells and xenograft models. Mechanistically, BCLET recognized and regulated AS of MSANTD2 to participate in bladder carcinogenesis, preferentially promoting the production of MSANTD2-004.

Conclusions: SNP rs558814 was associated with the expression of BCLET, which mainly increased the expression of MSANTD2-004 through AS of MSANTD2.

Citing Articles

Wang S, Qi X, Liu D, Xie D, Jiang B, Wang J Comput Struct Biotechnol J. 2024; 23:491-505.

PMID: 38249783 PMC: 10796827. DOI: 10.1016/j.csbj.2023.12.016.

LncRNA BCLET variant confers bladder cancer susceptibility through alternative splicing of MSANTD2 exon 1.

Liu H, Wang X, Guo Z, Sun G, Lv Q, Qin C Cancer Med. 2023; 12(13):14440-14451.

PMID: 37211917 PMC: 10358201. DOI: 10.1002/cam4.6072.

References

Sveen A, Kilpinen S, Ruusulehto A, Lothe R, Skotheim R . Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene. 2015; 35(19):2413-27. DOI: 10.1038/onc.2015.318. View

Tian J, Wang Z, Mei S, Yang N, Yang Y, Ke J . CancerSplicingQTL: a database for genome-wide identification of splicing QTLs in human cancer. Nucleic Acids Res. 2018; 47(D1):D909-D916. PMC: 6324030. DOI: 10.1093/nar/gky954. View

Bielli P, Bordi M, Di Biasio V, Sette C . Regulation of BCL-X splicing reveals a role for the polypyrimidine tract binding protein (PTBP1/hnRNP I) in alternative 5' splice site selection. Nucleic Acids Res. 2014; 42(19):12070-81. PMC: 4231771. DOI: 10.1093/nar/gku922. View

Islami F, Sauer A, Miller K, Siegel R, Fedewa S, Jacobs E . Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2017; 68(1):31-54. DOI: 10.3322/caac.21440. View

Wang E, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C . Alternative isoform regulation in human tissue transcriptomes. Nature. 2008; 456(7221):470-6. PMC: 2593745. DOI: 10.1038/nature07509. View

Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P . Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2012; 63(2):234-41. DOI: 10.1016/j.eururo.2012.07.033. View

Urbanski L, Leclair N, Anczukow O . Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. Wiley Interdiscip Rev RNA. 2018; 9(4):e1476. PMC: 6002934. DOI: 10.1002/wrna.1476. View

Wang M, Du M, Ma L, Chu H, Lv Q, Ye D . A functional variant in TP63 at 3q28 associated with bladder cancer risk by creating an miR-140-5p binding site. Int J Cancer. 2015; 139(1):65-74. DOI: 10.1002/ijc.29978. View

Wang M, Chu H, Lv Q, Wang L, Yuan L, Fu G . Cumulative effect of genome-wide association study-identified genetic variants for bladder cancer. Int J Cancer. 2014; 135(11):2653-60. DOI: 10.1002/ijc.28898. View

10.

Eichler E, Flint J, Gibson G, Kong A, Leal S, Moore J . Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet. 2010; 11(6):446-50. PMC: 2942068. DOI: 10.1038/nrg2809. View

11.

Braunschweig U, Gueroussov S, Plocik A, Graveley B, Blencowe B . Dynamic integration of splicing within gene regulatory pathways. Cell. 2013; 152(6):1252-69. PMC: 3642998. DOI: 10.1016/j.cell.2013.02.034. View

12.

Pan Q, Shai O, Lee L, Frey B, Blencowe B . Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008; 40(12):1413-5. DOI: 10.1038/ng.259. View

13.

Lim E, Uddin M, De Rubeis S, Chan Y, Kamumbu A, Zhang X . Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder. Nat Neurosci. 2017; 20(9):1217-1224. PMC: 5672813. DOI: 10.1038/nn.4598. View

14.

Mucci L, Hjelmborg J, Harris J, Czene K, Havelick D, Scheike T . Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA. 2016; 315(1):68-76. PMC: 5498110. DOI: 10.1001/jama.2015.17703. View

15.

Baralle F, Giudice J . Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017; 18(7):437-451. PMC: 6839889. DOI: 10.1038/nrm.2017.27. View

16.

Liu H, Wang X, Guo Z, Sun G, Lv Q, Qin C . LncRNA BCLET variant confers bladder cancer susceptibility through alternative splicing of MSANTD2 exon 1. Cancer Med. 2023; 12(13):14440-14451. PMC: 10358201. DOI: 10.1002/cam4.6072. View

17.

Kelemen O, Convertini P, Zhang Z, Wen Y, Shen M, Falaleeva M . Function of alternative splicing. Gene. 2012; 514(1):1-30. PMC: 5632952. DOI: 10.1016/j.gene.2012.07.083. View

18.

Li Y, van de Geijn B, Raj A, Knowles D, Petti A, Golan D . RNA splicing is a primary link between genetic variation and disease. Science. 2016; 352(6285):600-4. PMC: 5182069. DOI: 10.1126/science.aad9417. View

19.

Ule J, Blencowe B . Alternative Splicing Regulatory Networks: Functions, Mechanisms, and Evolution. Mol Cell. 2019; 76(2):329-345. DOI: 10.1016/j.molcel.2019.09.017. View

20.

Huang Z, Wang X, Ma L, Guo Z, Liu H, Du M . Genetic variations in Hippo pathway genes influence bladder cancer risk in a Chinese population. Arch Toxicol. 2020; 94(3):785-794. DOI: 10.1007/s00204-020-02663-z. View